BMRN
NASDAQ
US
BioMarin Pharmaceutical Inc. - Common Stock
$55.67
▲ +$0.17
(+0.31%)
Vol 45K
12
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$11.4B
P/E
21.9
ROE
8.8%
Margin
16.8%
D/E
9.85
Beta
0.26
52W
$51–$74
Wall Street Consensus
31 analysts · Apr 202610
Strong Buy
15
Buy
6
Hold
0
Sell
0
Strong Sell
80.6%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.64 | $-0.24 | $-0.88 |
| Sep 2025 | $0.38 | $-0.16 | $-0.54 |
| Jun 2025 | $0.85 | $1.23 | +$0.38 |
| Mar 2025 | $0.72 | $0.95 | +$0.23 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $747.3M | $745.1M | $825.4M | $776.1M | $874.6M |
| Net Income | $124.9M | $185.7M | $240.5M | -$30.7M | -$46.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 11.5% | 11.5% | 11.5% | 11.5% | 8.8% | 8.8% |
| P/E (TTM) | 16.04 | 17.06 | 16.21 | 15.66 | 20.09 | 21.94 |
| Net Margin | 29.1% | 21.4% | 21.4% | 21.4% | 16.8% | 16.8% |
| Gross Margin | 81.8% | 79.6% | 79.6% | 79.6% | 81.3% | 81.3% |
| D/E Ratio | 9.89 | 9.89 | 9.89 | 9.89 | 9.85 | 9.85 |
| Current Ratio | 5.56 | 5.56 | 5.56 | 5.56 | 4.83 | 4.83 |
Key Ratios
ROA (TTM)
7.1%
P/S (TTM)
3.69
P/B
2.2
EPS (TTM)
$2.64
CF/Share
$1.30
Rev Growth 3Y
+15.6%
52W High
$73.51
52W Low
$50.76
$50.76
52-Week Range
$73.51
Financial Health
Free Cash Flow
$56.6M
Net Debt
-$705.8M
Cash
$1.3B
Total Debt
$605.9M
As of Dec 31, 2025
How does BMRN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
BMRN valuation vs Biotechnology peers
P/E ratio
21.9
▲
17%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.7
▼
71%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.2
▼
10%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
BMRN profitability vs Biotechnology peers
ROE
8.8%
▲
113%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
16.8%
▲
106%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
81.3%
▲
3%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
7.1%
▲
115%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
BMRN financial health vs Biotechnology peers
D/E ratio
9.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.8
▲
9%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.3
▼
73%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
BMRN fundamentals radar
BMRN
Peer median
Industry
BMRN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BMRN vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
DAVIS GEORGE ERIC
Officer · Mar 16
14570 shs
GUYER CHARLES GREG
Chief Technology Officer · Mar 16
14990 shs
HARDY ALEXANDER
Chief Executive Officer · Mar 16
62440 shs
HUBBARD CRISTIN
Officer · Mar 16
15410 shs
FRIBERG GREGORY R
Officer · Mar 16
19150 shs
MUELLER BRIAN R
Chief Financial Officer · Mar 16
18740 shs
GUYER CHARLES GREG
Chief Technology Officer · Mar 11
16486 shs
DAVIS GEORGE ERIC
Officer · Feb 26
26061 shs
FRIBERG GREGORY R
Officer · Feb 26
6326 shs
DAVIS GEORGE ERIC
Officer · Feb 25
15224 shs
Last 90 days
Top Holders
Top 5: 38.45%Blackrock Inc.
9.95%
$1.1B
Vanguard Group Inc
9.43%
$1.0B
Dodge & Cox Inc.
7.58%
$808.8M
Primecap Management Company
7.57%
$807.5M
NORGES BANK
3.92%
$418.0M
As of Dec 31, 2025